Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:GAVI
gptkb:GAVI,_the_Vaccine_Alliance gptkb:Flavivirus |
| gptkbp:age |
recommended for 9 months and older
|
| gptkbp:airlines |
specific countries require vaccination
|
| gptkbp:availability |
widely available
|
| gptkbp:average_temperature |
2 to 8 ° C
|
| gptkbp:clinical_trial |
Phase I, II, III
|
| gptkbp:contraindication |
immunocompromised individuals
egg allergy pregnancy caution |
| gptkbp:defense |
routine vaccination in endemic areas
|
| gptkbp:developed_by |
gptkb:Max_Theiler
|
| gptkbp:dosage_form |
recommended after 10 years
|
| gptkbp:duration |
10 years
at least 10 years |
| gptkbp:first_introduced |
1937
|
| gptkbp:healthcare |
integrated into national immunization programs
reduced incidence of yellow fever |
| gptkbp:historical_significance |
contributed to public health advancements
|
| https://www.w3.org/2000/01/rdf-schema#label |
yellow fever vaccine
|
| gptkbp:is_vulnerable_to |
gptkb:historical_event
varies by region ongoing studies post-marketing surveillance 95% or higher requires cold chain required for entry into certain countries CDC guidelines important for travelers part of global health initiatives attenuated live virus developed from 17 D strain generally safe for healthy individuals high in endemic regions international travel clinics monitoring adverse effects prevention of outbreaks single dose sufficient single injection |
| gptkbp:manager |
subcutaneous
|
| gptkbp:manufacturer |
multiple pharmaceutical companies
|
| gptkbp:regulatory_compliance |
FDA approved
|
| gptkbp:research_focus |
improving efficacy and safety
|
| gptkbp:side_effect |
headache
muscle pain mild fever serious allergic reactions |
| gptkbp:suitable_for |
travelers to endemic areas
|
| gptkbp:targets |
gptkb:yellow_fever
|
| gptkbp:traded_on |
gptkb:YF-Vax
|
| gptkbp:type |
live attenuated vaccine
|